Dual neurohormonal intervention in CV disease: Angiotensin receptor and Neprilysin inhibition

Expert Opinion on Investigational Drugs

Volumn 22, Issue 7, 2013, Pages 915-925

  Segura, Julian ^a   Salazar, Jorge ^b   Ruilope, Luis M ^a,c  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b Novartis Pharmaceuticals   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Angiotensin receptor; Hypertension; LCZ696; Neprilysin inhibition

Indexed keywords

3 (1 BIPHENYL 4 YLMETHYL 3 CARBOXY 1 BUTYLCARBAMOYL)PROPIONIC ACID; 3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID; 3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID PLUS VALSARTAN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ENALAPRIL; ENKEPHALINASE INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; OMAPATRILAT; VALSARTAN;

ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; HEART FAILURE; HUMAN; HYPERTENSION; MAXIMUM PLASMA CONCENTRATION; PROTEIN BLOOD LEVEL; REVIEW; SYSTOLIC BLOOD PRESSURE;

AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; NEPRILYSIN; NEUROTRANSMITTER AGENTS; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; TREATMENT OUTCOME;

EID: 84879098362     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.797962     Document Type: Review

References (58)

1. Lawes CM, Vander HS, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008;371:1513-18
2. Mendis S, Puska P, Norrvin B. editors. Global atlas on cardiovascular disease prevention and control. World Health Organization, Geneva; 2011
3. Ruilope LM. Current challenges in the clinical management of hypertension. Nat Rev Cardiol 2011;9:267-75
4. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13
5. Perera GA. Hypertensive vascular disease; description and natural history. J Chronic Dis 1955;1:33-42
6. Ruilope LM. Can effectiveness of hypertension management be improved? Expert Rev Cardiovasc Ther 2013;In press
7. Ferdinand K, Saini R, Lewin A, et al. Efficacy and safety of omapatrilat with hydrochlorothiazide for the treatment of hypertension in subjects nonresponsive to hydrochlorothiazide alone. Am J Hypertens 2001;14(8 Pt 1):788-93
8. Campese VM, Lasseter KC, Ferrario CM, et al. Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients. Hypertension 2001;38:1342-8
9. Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004;17(2):103-11
10. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8
11. Pandey KN. Biology of natriuretic peptides and their receptors. Peptides 2005;26:901-32
12. Gardner DG, Chen S, Glenn DJ, et al. Molecular biology of the natriuretic peptide system: implications for physiology and hypertension. Hypertension 2007;49:419-26
13. Bevan EG, Connell JM, Doyle J, et al. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens 1992;10:607-13
14. Richards AM, Wittert GA, Crozier IG, et al. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens 1993;11:407-16
15. Ando S, Rahman MA, Butler GC, et al. Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension 1995;26:1160-6
16. Ferro CJ, Spratt JC, Haynes et al. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation 1998;97:2323-30
17. Campbell DJ. Vasopeptidase inhibition: a double-edged sword? Hypertension 2003;41:383-9
18. Ksander GM, Ghai RD, de Jesus R, et al. Dicarboxylic acid dipeptide neutral endopeptidase inhibitors. J Med Chem 1995;38:1689-700
19. Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor Neprilysin inhibitor (ARNI). J Clin Pharmacol 2010;50:401-14
20. Fryer RM, Segreti J, Banfor PN, et al. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol 2008;153:947-55
21. Kobalava Z, Averkov O, Meray I, et al. Natriuretic peptide inhibition in the presence of angiotensin receptor blockade following short-term treatment with LCZ696 in heart failure patients: effect on ANP, BNP, NT-proBNP and cGMP. Eur Heart J 2011;32(Abstract Suppl): 784-5
22. Steckelings UM, Paulis L, Namsolleck P, Unger T. AT2 receptor agonists: hypertension and beyond. Curr Opin Nephrol Hypertens 2012;21:142-6
23. Gwathmey TM, Alzayadneh EM, Pendergrass KD, Chappel MC. Novel roles of nuclear angiotensin receptors and signaling mechanisms. Am J Physiol Regul Integr Comp Physiol 2012;302:R518-30
24. Julius S, Kjeldsen SE, Weaber M, et al. For the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31
25. Solomon SD, Zelenkofske S, McMurray JJ, et al. Valsartan in Acute Myocardial Infarction Trial (VALIANT) Investigators. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 2005;352:2581-8
26. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75
27. McMurray JJ, Holman RR, Haffner SM, et al. NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1477-90
28. Sawada T, Yamada H, Dahlof B, et al. KYOTO HEART Study Group. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J 2009;30:2461-9
29. Mochizuki S, Dahlof B, Shimizu M, et al. Jikei Heart Study group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007;369:1431-9
30. Viberti G, Wheeldon NM; MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106:672-8
31. Segura J, Ruilope LM. Dual-acting angiotensin-receptor Neprilysin inhibition. Curr Hypertens Rep 2011;13:74-8
32. Burnett JC Jr. Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens 1999;17(Suppl 1):S37-43
33. Fryer RM, Segreti J, Banfor PN, et al. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol 2008;153:947-55
34. Ruilope LM, Dukat A, Bohm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and Neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010;375:1255-66
35. Kobalava Z, Kotovskaya Y, Meray I, et al. Clinic blood pressure in stable heart failure patients treated with the dual-acting Neprilysin and angiotensin receptor inhibitor LCZ696. Eur Heart J 2011;32(Abstract Suppl):788
36. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor Neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012;380:1387-95
37. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91
38. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302
39. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999;100:2312-18
40. Granger CB, McMurray JJ, Yusuf S, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin- convertingenzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-6
41. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17
42. Zannad F, McMurray JJ, Krum H, et al. EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21
43. Pitt B, Remme W, Zannad F, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21
44. McMurray JJ, Ostergren J, Swedberg K, CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362(9386):767-71
45. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-847
46. Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993;153(8):937-42
47. Anand IS, Fisher LD, Chiang YT, Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107(9):1278-83
48. Rouleau JL, Pfeffer MA, Stewart DJ, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000;356:615-20
49. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE). Circulation 2002;106:920-6
50. A Multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of lcz696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction. Available from: http://clinicaltrials.gov/ct2/ show/NCT01035255 [Access 13 January 2013]
51. Martínez-Sellés M, García Robles JA, Prieto L, et al. Annual rates of admission and seasonal variations in hospitalizations for heart failure. Eur J Heart Fail 2002;4:779-86
52. Fonarow GC, Stough WG, Abraham WT, et al. OPTIMIZE-HF Investigators and Hospitals. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry. J Am Coll Cardiol 2007;50(8):768-77
53. Quirós López R, García Alegría J, Martín Escalante MD, et al. Prognostic factors and long-term survival after initial diagnosis of heart failure. Med Clin (Barc) 2012;138:602-8
54. Rodríguez-Artalejo F, Banegas Banegas JR, Guallar-Castillón P. Epidemiology of heart failure. Rev Esp Cardiol 2004;57:163-70
55. Cleland JG, Clark AL. Heart failure-does it matter whether LVEF is reduced? Lancet 2012;380:1363-5
56. Cuculi F, Erne P. Combined neutral endopeptidase inhibitors. Expert Opin Investig Drugs 2011;20:457-63
57. Available from: http://clinicaltrials.gov/ct2/results?term=lcz696
58. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008;51:1403-19